What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on the patient's eye after crosslinking. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.”In the company’s words, NCT06450470 on ClinicalTrials.gov
- Tested for
- Progressive Keratoconus
- Main trialPhase 3
- “Crosslinking is a therapeutic technique used to increase the rigidity of the cornea in order to slow or stop progression of keratoconus. The main complication of the treatment of keratoconus by crosslinking is postoperative pain due to the removal of the corneal epithelium. Currently, the management of pain is done through the administration of artificial tears and paracetamol. The amniotic membrane is a biological tissue used in ophthalmology to treat injuries of the surface of the eye. It has healing and analgesic properties. The objective of this multicenter randomized study is to…”In the company’s words, NCT06450470 on ClinicalTrials.gov
Other drugs for Progressive Keratoconus
- Riboflavin 0.1% ophthalmic solutionPrice Vision Group · Phase 2/3
- TGF-B3 and Dexamethasone Sodium PhosphateTheiaNova Ltd. · Phase 1/2
- GLK-221Glaukos Corporation · Phase 2
- Riboflavin Ophthalmic SolutionsGlaukos Corporation · Marketed (Phase 4 trial)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Nov 2025 | Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus | |
| Phase 2Terminated | 10 Oct 2022 | Amniotic Membrane Visio-AMTRIX in Recurrent Macular Hole |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026